GSK reports Mo-Rez ovarian cancer trial shows 62% confirmed response rate, 11.1-month PFS

GSK reported its Mo-Rez ovarian cancer trial showed a 62% confirmed objective response rate with a 12.2-month median response duration, and an 11.1-month median progression-free survival in platinum-resistant ovarian cancer.

Detected & updated continuously · Source: Nebula